Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas-Reference-Cited by-同舟云学术

Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas

Published:2024-06 Issue:4 Volume:25 Page:389-394
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Okuma Yusuke^ORCID,Nomura Shogo,Sakakibara-Konishi Jun,Tsukita Yoko,Murakami Shuji,Hosomi Yukio,Tambo Yuichi,Kogure Yoshihito,Yoshioka Hiroshige,Tamiya Motohiro,Ninomiya Kiichiro,Iwama Eiji

Funder

MSD

Merck Sharp and Dohme K.K.

Meso Scale Diagnostics

Publisher

Elsevier BV

Reference18 articles.

1. Mutational heterogeneity in cancer and the search for new cancer-associated genes;Lawrence;Nature,2013

2. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors;Petrini;Nat Genet,2014

3. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma;Katsuya;Lung Cancer,2015

4. Downregulation of CYLD promotes IFN-γ mediated PD-L1 expression in thymic epithelial tumors;Umemura;Lung Cancer,2020

5. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial;Cho;J Clin Oncol,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving treatment landscape in thymic epithelial tumors: From mechanism to therapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Study on Cytochrome P450 Metabolic Profile of Paclitaxel on Rats using QTOF-MS;Current Drug Metabolism;2024-07-19